BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 68] [Article Influence: 21.7] [Reference Citation Analysis]
Number Citing Articles
1 Huo Q, Hu J, Hou B, Zhao M, Han X, Du Y, Li Y. Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients. Pathol Oncol Res 2022;28. [DOI: 10.3389/pore.2022.1610396] [Reference Citation Analysis]
2 Izzo F, Mason MC, Silberfein EJ, Massarweh NN, Hsu C, Tran Cao HS, Palaia R, Piccirillo M, Belli A, Patrone R, Fusco R, Granata V, Curley SA. Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening. Biology 2022;11:1597. [DOI: 10.3390/biology11111597] [Reference Citation Analysis]
3 Nevarez NM, Chang GY, Yopp AC. An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2022.07.008] [Reference Citation Analysis]
4 Nelson DW, Vauthey J. Optimizing Treatment Strategies with Preoperative Assessment for Microvascular Invasion in Hepatocellular Carcinoma. Ann Surg Oncol 2022. [DOI: 10.1245/s10434-022-12746-z] [Reference Citation Analysis]
5 Yang SC, Liang L, Wang MD, Wang XM, Gu LH, Lin KY, Zhou YH, Chen TH, Gu WM, Li J, Wang H, Chen Z, Li C, Yao LQ, Diao YK, Sun LY, Zhang CW, Zeng YY, Lau WY, Huang DS, Shen F, Yang T. Prospective validation of the Eastern Staging in predicting survival after surgical resection for patients with hepatocellular carcinoma: a multicenter study from China. HPB (Oxford) 2022:S1365-182X(22)01592-1. [PMID: 36167767 DOI: 10.1016/j.hpb.2022.09.002] [Reference Citation Analysis]
6 Kim S, Park K, Lim JH, Yun HJ, Kim SY, Choi KH, Kim CW, Lee JH, Weicker R, Pan C, Park KC. Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma. IJMS 2022;23:10378. [DOI: 10.3390/ijms231810378] [Reference Citation Analysis]
7 Wang MD, Xiang H, Zhang L, Wang C. Integration of OV6 expression and CD68+ tumor-associated macrophages with clinical features better predicts the prognosis of patients with hepatocellular carcinoma. Transl Oncol 2022;25:101509. [PMID: 36030750 DOI: 10.1016/j.tranon.2022.101509] [Reference Citation Analysis]
8 Wang K, Ye X, Yin C, Ren Q, Chen Y, Qin X, Duan C, Lu A, Gao L, Guan D. Computational Metabolomics Reveals the Potential Mechanism of Matrine Mediated Metabolic Network Against Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:859236. [DOI: 10.3389/fcell.2022.859236] [Reference Citation Analysis]
9 Lim JH, Park K, Choi KH, Kim CW, Lee JH, Weicker R, Pan C, Kim S, Park KC. Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma. IJMS 2022;23:7971. [DOI: 10.3390/ijms23147971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5:e2222721. [PMID: 35849393 DOI: 10.1001/jamanetworkopen.2022.22721] [Reference Citation Analysis]
11 Parks LS, Little P. Cirrhosis, Hepatocellular Carcinoma, and Locoregional Therapies. Journal of Radiology Nursing 2022;41:129-135. [DOI: 10.1016/j.jradnu.2022.01.005] [Reference Citation Analysis]
12 Lin Z, Huang X, Ji X, Tian N, Gan Y, Ke L. Analysis of multiple databases identifies crucial genes correlated with prognosis of hepatocellular carcinoma. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-13159-4] [Reference Citation Analysis]
13 Yu M, Zhang C, Tang H, Xiao C. Correlation between Serum Oxidative Stress Level and Serum Uric Acid and Prognosis in Patients with Hepatitis B-Related Liver Cancer before Operation. J Healthc Eng 2022;2022:1964866. [PMID: 35449838 DOI: 10.1155/2022/1964866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Vène E, Jarnouen K, Ribault C, Vlach M, Verres Y, Bourgeois M, Lepareur N, Cammas-marion S, Loyer P. Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl malate)-Based Nanoparticles in Human Hepatoma Cells. Pharmaceutics 2022;14:804. [DOI: 10.3390/pharmaceutics14040804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Youn SY, Kim B, Kim DH, Choi HJ, Sung PS, Choi J. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy–treated hepatocellular carcinoma. Eur Radiol. [DOI: 10.1007/s00330-022-08720-8] [Reference Citation Analysis]
16 Shi C, Li Y, Geng L, Shen W, Sui C, Dai B, Lu J, Pan M, Yang J. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. Eur J Cancer 2022;166:176-84. [PMID: 35303509 DOI: 10.1016/j.ejca.2022.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Yao LQ, Chen ZL, Feng ZH, Diao YK, Li C, Sun HY, Zhong JH, Chen TH, Gu WM, Zhou YH, Zhang WG, Wang H, Zeng YY, Wu H, Wang MD, Xu XF, Pawlik TM, Lau WY, Shen F, Yang T. Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Ann Surg Oncol 2022. [PMID: 35192156 DOI: 10.1245/s10434-022-11454-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Jian J, Nie Y, Huang C, Wan S, Zhu X. A scoring model predicting overall survival for hepatocellular carcinoma patients who receive surgery and chemotherapy. Indian J Surg. [DOI: 10.1007/s12262-021-03224-z] [Reference Citation Analysis]
19 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021;27:8069-80. [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
21 Wu H, Zhang J, Bai Y, Zhang S, Zhang Z, Tong W, Han P, Fu B, Zhang Y, Shen Z. DCP1A is an unfavorable prognostic-related enhancer RNA in hepatocellular carcinoma. Aging (Albany NY) 2021;13:23020-35. [PMID: 34609335 DOI: 10.18632/aging.203593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Peng B, Yan Y, Xu Z. The bioinformatics and experimental analysis of AlkB family for prognosis and immune cell infiltration in hepatocellular carcinoma. PeerJ 2021;9:e12123. [PMID: 34557360 DOI: 10.7717/peerj.12123] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhang Y, Zuo Z, Liu B, Yang P, Wu J, Han L, Han T, Chen T. FAT10 promotes hepatocellular carcinoma (HCC) carcinogenesis by mediating P53 degradation and acts as a prognostic indicator of HCC. J Gastrointest Oncol 2021;12:1823-37. [PMID: 34532131 DOI: 10.21037/jgo-21-374] [Reference Citation Analysis]
25 Lu T, Wei L, Huang X, Li Y, Li G, Qin Q, Pan M, Tang B, Pan X, Wei M, Nong Z, Meng F, Li X. A potentially valuable nano graphene oxide/USPIO tumor diagnosis and treatment system. Mater Sci Eng C Mater Biol Appl 2021;128:112293. [PMID: 34474844 DOI: 10.1016/j.msec.2021.112293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fulgenzi CAM, Talbot T, Murray SM, Silletta M, Vincenzi B, Cortellini A, Pinato DJ. Immunotherapy in Hepatocellular Carcinoma. Curr Treat Options Oncol 2021;22:87. [PMID: 34424422 DOI: 10.1007/s11864-021-00886-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
27 Elfadaly AN, Tsilimigras DI, Hyer JM, Paro A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Impact of Tumor Burden Score on Conditional Survival after Curative-Intent Resection for Hepatocellular Carcinoma: A Multi-Institutional Analysis. World J Surg 2021. [PMID: 34341844 DOI: 10.1007/s00268-021-06265-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 2021;13:17588359211031141. [PMID: 34377156 DOI: 10.1177/17588359211031141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Luo YC, Lu HL, Song WL, Xuan FF. Multidisciplinary treatment of advanced hepatocellular carcinoma with severe arterioportal shunt: a case report. J Int Med Res 2021;49:3000605211024840. [PMID: 34250825 DOI: 10.1177/03000605211024840] [Reference Citation Analysis]
30 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
31 Fancellu A, Sanna V, Scognamillo F, Feo CF, Vidili G, Nigri G, Porcu A. Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations. World J Clin Cases 2021; 9(15): 3517-3530 [PMID: 34046452 DOI: 10.12998/wjcc.v9.i15.3517] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Wei T, Zhang XF, Xue F, Bagante F, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34019181 DOI: 10.1245/s10434-021-10142-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 27.0] [Reference Citation Analysis]
34 Jeong YH, Hwang S, Lee GD, Choi SH, Kim HR, Kim YH, Park SI, Kim DK. Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Ann Transplant 2021;26:e930383. [PMID: 33972494 DOI: 10.12659/AOT.930383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Xin F, Wu M, Cai Z, Zhang X, Wei Z, Liu X, Liu J. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;10:e2002036. [PMID: 33644987 DOI: 10.1002/adhm.202002036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
36 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
37 Yang F, Yan Z, Nie W, Liu Z, Cheng X, Wang W, Shao C, Fu G, Yu Y. LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S-1. Oncol Lett 2021;21:470. [PMID: 33907580 DOI: 10.3892/ol.2021.12731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Brossard C, Vlach M, Vène E, Ribault C, Dorcet V, Noiret N, Loyer P, Lepareur N, Cammas-Marion S. Synthesis of Poly(Malic Acid) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells. Nanomaterials (Basel) 2021;11:958. [PMID: 33918663 DOI: 10.3390/nano11040958] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
39 Montasser A, Beaufrère A, Cauchy F, Bouattour M, Soubrane O, Albuquerque M, Paradis V. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 2021;79:36-46. [PMID: 33326644 DOI: 10.1111/his.14317] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
40 Tampaki M, Papatheodoridis GV, Cholongitas E. Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clin J Gastroenterol 2021;14:699-713. [PMID: 33774785 DOI: 10.1007/s12328-021-01394-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
41 Oyama A, Nouso K, Yoshimura K, Morimoto Y, Nakamura S, Onishi H, Takaki A, Iwadou S, Kariyama K, Kuwaki K, Yabushita K, Sakaguchi K, Toshimori J, Kobashi H, Moriya A, Ando M, Okada H; Okayama Hepatocellular Carcinoma Study Group. Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2021;51:694-701. [PMID: 33687130 DOI: 10.1111/hepr.13633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
42 Ishinuki T, Ota S, Harada K, Tatsumi H, Harada K, Miyanishi K, Nagayama M, Takemasa I, Ohyanagi T, Hui TT, Mizuguchi T. Health-related quality of life in patients that have undergone liver resection: A systematic review and meta-analysis. World J Meta-Anal 2021; 9(1): 88-100 [DOI: 10.13105/wjma.v9.i1.88] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bergquist JR, Li AY, Javadi CS, Lee B, Norton JA, Poultsides GA, Dua MM, Visser BC. Regional lymph node sampling in hepatoma resection: insight into prognosis. HPB (Oxford) 2021:S1365-182X(21)00007-1. [PMID: 33563547 DOI: 10.1016/j.hpb.2021.01.006] [Reference Citation Analysis]
44 Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel) 2021;14:43. [PMID: 33429973 DOI: 10.3390/ph14010043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
45 Choi GH. Neoadjuvant Radiotherapy Converting to Curative Resection. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_15] [Reference Citation Analysis]
46 Wang Q, Huang J, Zhang H, Liu H, Yu M. Identification and analysis of immune-related subtypes of hepatocellular carcinoma. Exp Biol Med (Maywood) 2021;246:667-77. [PMID: 33231514 DOI: 10.1177/1535370220970130] [Reference Citation Analysis]
47 Wang M, Huang S, Chen Z, Han Z, Li K, Chen C, Wu G, Zhao Y. Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer 2020;20:1136. [PMID: 33228611 DOI: 10.1186/s12885-020-07625-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
48 Shinkawa H, Tanaka S, Takemura S, Amano R, Kimura K, Kinoshita M, Takahashi K, Matsuzaki S, Kubo S. Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma. Surgery 2021;169:922-8. [PMID: 33190917 DOI: 10.1016/j.surg.2020.10.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
49 Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncology 2020;16:2587-9. [DOI: 10.2217/fon-2020-0669] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
50 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(10): 693-708 [PMID: 33200010 DOI: 10.4254/wjh.v12.i10.693] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
51 Wang Z, Zhang N, Lv J, Ma C, Gu J, Du Y, Qiu Y, Zhang Z, Li M, Jiang Y, Zhao J, Du H, Zhang Z, Lu W, Zhang Y. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients. Biomed Res Int 2020;2020:4037639. [PMID: 33163533 DOI: 10.1155/2020/4037639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
54 Zhu HB, Zheng ZY, Zhao H, Zhang J, Zhu H, Li YH, Dong ZY, Xiao LS, Kuang JJ, Zhang XL, Liu L. Radiomics-based nomogram using CT imaging for noninvasive preoperative prediction of early recurrence in patients with hepatocellular carcinoma.Diagn Interv Radiol. 2020;26:411-419. [PMID: 32490826 DOI: 10.5152/dir.2020.19623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
55 Wang Z, Duan Y, Zhang J, Lv Y, Wu S, Cheng M, Bhagavathula AS, Aldhaleei WA, Clark C, Huo Z. Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A meta-analysis. Eur J Pharmacol 2020;883:173382. [PMID: 32693099 DOI: 10.1016/j.ejphar.2020.173382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 18.5] [Reference Citation Analysis]
57 Gautier SV, Monakhov AR, Tsirulnikova OM, Zubenko SI, Sitnikova EV, Umrik DV, Nosov KA, Kurtak ND. Outcomes of liver transplantation in hepatocellular carcinoma: a single-center experience. Ann hir gepatol 2020;25:67-76. [DOI: 10.16931/1995-5464.2020267-76] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Afaloniati H, Angelopoulou K, Giakoustidis A, Hardas A, Pseftogas A, Makedou K, Gargavanis A, Goulopoulos T, Iliadis S, Papadopoulos V, Papalois A, Mosialos G, Poutahidis T, Giakoustidis D. HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice. Onco Targets Ther 2020;13:5575-88. [PMID: 32606772 DOI: 10.2147/OTT.S250233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
59 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
60 Shi C, Yang H, Zhang Z. Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases. Front Cell Dev Biol 2020;8:139. [PMID: 32211410 DOI: 10.3389/fcell.2020.00139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
61 Yu B, Liang H, Ye Q, Wang Y. Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection. J Gastrointest Surg 2021;25:112-24. [PMID: 32128678 DOI: 10.1007/s11605-020-04554-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
62 Hectors SJ, Lewis S, Besa C, King MJ, Said D, Putra J, Ward S, Higashi T, Thung S, Yao S, Laface I, Schwartz M, Gnjatic S, Merad M, Hoshida Y, Taouli B. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol. 2020;30:3759-3769. [PMID: 32086577 DOI: 10.1007/s00330-020-06675-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 21.5] [Reference Citation Analysis]
63 Lang H, Heinrich S, Bartsch F, Hüttl F, Baumgart J, Mittler J. [Surgical treatment of hepatic tumors-liver resection and transplantation]. Internist (Berl) 2020;61:147-57. [PMID: 32016491 DOI: 10.1007/s00108-020-00754-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]